Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Globalspace Technologies Ltd
BSE:540654
|
IN |
Salarius Pharmaceuticals Inc
EPS (Diluted)
Salarius Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
EPS (Diluted)
-$10
|
CAGR 3-Years
81%
|
CAGR 5-Years
62%
|
CAGR 10-Years
61%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Salarius Pharmaceuticals Inc
Glance View
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.
See Also
What is Salarius Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-10.4
USD
Based on the financial report for Sep 30, 2025, Salarius Pharmaceuticals Inc's EPS (Diluted) amounts to -10.4 USD.
What is Salarius Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
61%
Over the last year, the EPS (Diluted) growth was 82%. The average annual EPS (Diluted) growth rates for Salarius Pharmaceuticals Inc have been 81% over the past three years , 62% over the past five years , and 61% over the past ten years .
